OncoMatch/Clinical Trials/NCT06503107
Nanobody-based Biepitope CAR-T Cells Targeting BCMA in the Treatment of R/RMM
Is NCT06503107 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies Nanobody-based biepitope BCMA-targeting CAR-T cells for multiple myeloma.
Treatment: Nanobody-based biepitope BCMA-targeting CAR-T cells — To explore the safety and efficacy of nanobody-based BCMA-targeting biepitope CAR-T cells in the treatment of relapsed/refractory multiple myeloma，this study will be conducted in multiple study centers, with 60 patients openly enrolled to receive CAR-T cell therapy. Patients participating in clinical trials will be tested and evaluated for treatment safety, efficacy, duration of response, and long-term survival.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Biomarker criteria
Required: BCMA (TNFRSF17) overexpression (positive by flow cytometry or immunohistochemistry)
Flow cytometry or immunohistochemistry showed positive BCMA expression in myeloma cells
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: cytotoxic chemotherapy
relapse is defined as disease progression within 60 days of the most recent treatment with three or more lines of therapy with different mechanisms of action
Cannot have received: antibody-based drugs
Have not been treated with antibody-based drugs within 2 weeks prior to cell therapy
Lab requirements
Blood counts
hgb≥70g/l，plt≥30×10^9/l
Kidney function
serum creatinine ≤ 1.5× uln or creatinine clearance (cockcroft-gault) >30 ml/min
Liver function
total bilirubin ≤ 1.5×uln; alt and ast ≤2.5×uln
Cardiac function
left ventricular ejection fraction (lvef) ≥50%, baseline peripheral oxygen saturation > 90%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify